Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Richard Weisler

Psychiatry Raleigh, NC Medical Doctor

NPI 1356522809 CMS profile 16673

700 Spring Forest Rd, Ste 125, Raleigh, NC 27609

Open in the dashboard

General payments

$107,859

179 records reported · program years 2019–2024

Research payments

$1,093,745

Paid to them · 34 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,073,073 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Richard Weisler of Raleigh, NC is reported in the CMS Open Payments database as having received $107,859 across 179 general payments and $1,093,745 in research payments paid to them. Separately, studies naming them as principal investigator received $1,073,073 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $181 2
2024 Research $28,492 1
2023 General $19,722 28
2023 Research $102,288 3
2022 General $32,498 47
2022 Research $206,942 1
2021 General $9,752 15
2021 Research $219,157 4
2020 General $2,363 5
2020 Research $532,426 6
2019 General $43,343 82
2019 Research $4,439 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Weisler
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Richard Weisler were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Richard Weisler Psychiatry median Middle half National median
2019 $43,343 $184 $59–$605 $163
2020 $2,363 $119 $36–$372 $114
2021 $9,752 $143 $43–$576 $132
2022 $32,498 $153 $50–$590 $149
2023 $19,722 $170 $56–$651 $160
2024 $181 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Supernus Pharmaceuticals, Inc. $43,186 38 payments
  2. Ironshore Pharmaceuticals Inc. $23,362 44 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $13,375 19 payments
  4. Otsuka America Pharmaceutical, Inc. $10,096 7 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $7,567 11 payments
  6. Janssen Pharmaceuticals, Inc $5,488 14 payments
  7. Validus Pharmaceuticals LLC $1,585 6 payments
  8. AbbVie, Inc. $819 11 payments
  9. Neos Therapeutics, LP $671 2 payments
  10. ITI, Inc. $631 10 payments
  11. Other $1,079 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $71,176 35 payments
  2. Consulting Fee $22,965 7 payments
  3. Food and Beverage $6,841 104 payments
  4. Travel and Lodging $5,371 29 payments
  5. Honoraria $1,500 1 payment
  6. Education $3 1 payment
  7. Gift $2 2 payments
Products named General payments · program years 2019–2024
  1. QELBREE $39,618 35 payments
  2. Jornay PM 20mg capsules (Bottle of 100) $23,284 43 payments
  3. REXULTI $7,051 10 payments
  4. Vyvanse Central Nervous System (CNS) $6,580 9 payments
  5. SPRAVATO $5,376 13 payments
  6. Equetro $1,584 5 payments
  7. VYVANSE Neuroscience $975 1 payment
  8. VRAYLAR $819 11 payments
  9. Adzenys XR-ODT $671 2 payments
  10. COTEMPLA XR-ODT $671 2 payments
  11. Other $2,683 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,093,745 34 payments

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record